Association of Receipt of Human Papillomavirus Vaccination and Personal History of Cancer Diagnosis in the United States: A Cross-Sectional Study Using NHIS Data

Abstract

Simple Summary Cancer survivors are at increased risk of subsequent HPV-associated malignancies. Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers (COG LTFU Guidelines) recommend that cancer survivors receive a 3-dose HPV vaccine series, starting 6 months after cancer treatment. We used data from the National Health Interview Surveys to study how the personal history of cancer diagnosis is associated with the receipt of HPV vaccination. We found that adults with a personal history of cancer diagnosis had significantly lower odds of receipt of HPV vaccination compared to adults without a personal history of cancer diagnosis. Smokers, non-US-born, uninsured, and living in non-metro areas had significantly lower odds of HPV vaccination. While adults aged 18–26 years, females, non-Hispanic others, highly educated, and living in rented houses had significantly higher odds of HPV vaccination. This study emphasizes the need for targeted evidence-based interventions to improve the receipt of HPV vaccination among cancer survivors.